May 15, 2019REGENXBIO to Launch New Manufacturing Facility for NAV Technology-based AAV Gene Therapies
May 7, 2019REGENXBIO Reports First Quarter 2019 Financial and Operating Results and Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD
October 26, 2018Six Month Results of the Phase I Study to Evaluate Safety & Tolerability of RGX-314 Gene Therapy in nAMD SubjectsJeffrey Heier, MD – Ophthalmic Consultants of Boston
May 15, 2018AAV8-antiVEGFfab Ocular Gene Transfer for Neovascular Age-Related MacularDegenerationREGENXBIO
January 12, 2018Adeno-Associated Virus Serotype 8 Gene Therapy Leads to Significant Lowering of Plasma Cholesterol Levels in Humanized Mouse Models of Homozygous and Heterozygous Familial HypercholesterolemiaREGENXBIO
